Identity
- Security key
- 16295
- Ticker
- GTBP
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2021-02-11
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- GTBP
Detail
Enriched 2026-08-14 20:47
- Market cap
- $10,894,603.3
- Shares outstanding (class)
- 44,338,573
- Shares outstanding (weighted)
- 36,062,904
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 1
- Location
- SAN FRANCISCO, CA
- Homepage
- https://www.gtbiopharma.com
- Description
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.